As discussed above, a number of mechanisms can lead to primary or acquired resistance of cancer cells to mTOR inhibitors, including activation of alternative pathways, due to other mutations, and excessive reactivation of AKT feedback resulting in overactivation of the insulin-growth factor. The gene discussed is MTOR; the disease is cancer.